Cas:4100-17-8 [1,2,3]Thiadiazole-4-carbonyl chloride manufacturer & supplier

Chemical Name:[1,2,3]Thiadiazole-4-carbonyl chloride

CAS.NO:4100-17-8

Synonyms:thiadiazole-4-carbonyl chloride

Molecular Formula:C₃HClN₂OS

Molecular Weight:148.57100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:71.09000

Exact Mass:147.95000

LogP:0.91710

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like thiadiazole-4-carbonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,thiadiazole-4-carbonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,thiadiazole-4-carbonyl chloride Use and application,thiadiazole-4-carbonyl chloride technical grade,usp/ep/jp grade.

Related News: Chinese officials on Sunday reported a surge in new cases. [1,2,3]Thiadiazole-4-carbonyl chloride manufacturer First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. [1,2,3]Thiadiazole-4-carbonyl chloride supplier Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. [1,2,3]Thiadiazole-4-carbonyl chloride vendor Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. [1,2,3]Thiadiazole-4-carbonyl chloride factory First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s.